Susan Blaney

Susan Blaney has led pediatric phase I clinical trial consortia that have been essential for evaluating immunotherapies in children, establishing safety and dosing for agents including checkpoint inhibitors and antibody-drug conjugates in pediatric populations. Her expertise in CNS tumor drug development has advanced immunotherapy strategies that address the unique challenges of the blood-brain barrier in pediatric brain tumors. She has been a driving force in advocating for pediatric-specific immunotherapy development pathways.